Therefore, the observations of the opposing effects of rapamycin on normal hematopoietic and leukemia stem cells or the preferential sensitivity of CSCs to mTOR inhibition compared with normal cells cannot be explained only by the shared function of the stemness pathways. The gene discussed is MTOR; the disease is leukemia.